Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 66, 455-70

Synthetic Lethality and Cancer Therapy: Lessons Learned From the Development of PARP Inhibitors

Affiliations
Review

Synthetic Lethality and Cancer Therapy: Lessons Learned From the Development of PARP Inhibitors

Christopher J Lord et al. Annu Rev Med.

Abstract

The genetic concept of synthetic lethality, in which the combination or synthesis of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to cancer. Already there are promising indications, from clinical trials exploiting this concept by using poly(ADP-ribose) polymerase (PARP) inhibitors in patients with germline BRCA1 or BRCA2 gene mutations, that this approach could be beneficial. We discuss the biological rationale for BRCA-PARP synthetic lethality, how the synthetic lethal approach is being assessed in the clinic, and how mechanisms of resistance are starting to be dissected. Applying the synthetic lethal concept to target non-BRCA-mutant cancers also has clear potential, and we discuss how some of the principles learned in developing PARP inhibitors might also drive the development of additional genetic approaches.

Keywords: BRCA1; BRCA2; breast cancer; drug resistance; ovarian cancer.

Similar articles

See all similar articles

Cited by 124 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback